US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

0.5685 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Traws Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
TRAW Stock Earnings: Traws Pharma Reported Results for Q2 2024 ↗
Traws Pharma just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Monday's pre-market session: top gainers and losers ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Thursday's pre-market session: top gainers and losers ↗
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November ↗
 
Via Benzinga
News headline image
Crude Oil Gains 1%; Chicago PMI Falls In December ↗
 
Via Benzinga
News headline image
US Stocks Open Lower; Dow Tumbles 600 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gold Moves Lower, Rumble Shares Jump ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November ↗
 
Via Benzinga
News headline image
Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results ↗
Traws Pharma (NASDAQ: TRAW) shares soar as company reports positive results for single-dose treatment of H5N1 bird flu. No adverse events reported. 
Via Benzinga
News headline image
US Stocks Mixed, Dow Tumbles 150 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >